Latest Breaking News On - Upcoming milestones - Page 11 : comparemela.com

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkBaden wübergAlexander fudukidisdirectorArtiva alloAdi hoessAffimedn vaffimedYago nietoUniversity of texas md anderson cancer centerAmerican society of hematologyInternational accounting standard boardExchange commissionSilicon valley bankProgram updatesInternational financial reporting standardsAmerican society

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerRisvodetinib ikAlex loboInhibikase or companySternir incInhibikase therapeutics incEuropean unionExchange commissionMovement disorder congressCompany contactHighlights recent periodAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestones

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course

United statesAlex loboRisvodetinib ikMiltonh wernerCompany contactExchange commissionSternir incInhibikase therapeutics incEuropean unionInhibikase or companyMovement disorder congressAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestonesOrphan drug designation

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage phar.

United statesMiltonh wernerRisvodetinib ikAlex loboInhibikase therapeutics incCompany contactMovement disorder congressInhibikase or companyEuropean unionSternir incExchange commissionAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestonesOrphan drug designation

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Kiora Pharmaceuticals, Inc : Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesBrianm stremKiora pharmaceuticalsAmerican academy of ophthalmologyCalifornia newsfile corpKiora pharmaceuticals incChoroideremia research foundationOrphan drugUpcoming milestonesAmerican academyReceived investigational new drug applicationCorneal epithelial defectEuropean patentsAppointed praveen tylePursue orphan drug designations